FaDu Xenograft Rat Model Service for Head and Neck Cancer

The FaDu xenograft rat model offers a well-established platform for investigating head and neck squamous cell carcinoma (HNSCC), leveraging a human hypopharyngeal cell line with documented sensitivity to EGFR-targeted agents and radiation modalities. Alfa Cytology delivers precision-engineered FaDu xenograft rat studies designed to accelerate your HNSCC therapeutic pipeline, combining rigorous tumor biology characterization with flexible endpoint analyses that inform critical preclinical decision-making from lead optimization through candidate prioritization.

Overview of FaDu Xenograft Rat Model for Head and Neck Cancer

The FaDu cell line was originally established from a biopsy specimen obtained from a 56-year-old Caucasian male patient diagnosed with squamous cell carcinoma of the hypopharynx, a subsite within the upper aerodigestive tract that carries a particularly poor prognosis due to late-stage presentation and limited therapeutic options. As one of the most extensively characterized head and neck cancer cell lines in preclinical oncology, FaDu has served as the foundational model for investigating drug response, radiation biology, and tumor microenvironment interactions across hundreds of published studies. When engrafted into immunodeficient rats, FaDu cells reliably form well-vascularized, moderately differentiated squamous tumors that retain key molecular hallmarks of human HNSCC, including constitutive overexpression of epidermal growth factor receptor (EGFR), mutant TP53, and disrupted cell-cycle regulation through CDKN2A inactivation—features that render this model especially pertinent for evaluating EGFR inhibitors, DNA-damaging agents, and combination regimens targeting the DNA damage response axis.

Fig 1. Using the FaDu subcutaneous xenograft model to evaluate the anti-tumor effect of SKLB188 (an EGFR inhibitor). (Barzegar, Mansoureh, et al., 2017)

In the rat xenograft setting, FaDu tumors typically establish within 10–14 days following subcutaneous inoculation and exhibit predictable exponential growth kinetics, with doubling times that facilitate robust statistical power even in modestly sized cohorts. The model's inherent radiosensitivity—attributable in part to mutant p53-mediated impairment of DNA repair—has made it an indispensable tool for preclinical radiotherapy studies, including fractionation schedule optimization and radiosensitizer screening. Additionally, FaDu cells produce proinflammatory cytokines and demonstrate neutrophil-activating capacity in vitro, suggesting utility for immuno-oncology investigations that probe tumor-stromal crosstalk. The rat host offers practical advantages over murine systems in terms of larger blood volumes for serial pharmacokinetic sampling, greater tissue mass for comprehensive biomarker analysis, and enhanced feasibility for localized radiation delivery using clinical-scale equipment.

Cell Line Information: FaDu

The FaDu cell line represents a cornerstone resource in head and neck squamous cell carcinoma research, derived from a well-documented clinical specimen and extensively characterized at the molecular, phenotypic, and functional levels. Its widespread availability through major biorepositories and robust tumorigenicity in immunodeficient hosts have cemented its status as a preferred model for HNSCC preclinical investigations. The following table summarizes the essential characteristics of the FaDu cell line.

Our Services

Alfa Cytology brings specialized expertise in head and neck oncology preclinical model development, offering comprehensive FaDu xenograft rat model services that encompass study design, tumor implantation, longitudinal monitoring, and multi-modal endpoint characterization. We recognize that each HNSCC therapeutic program presents distinct analytical challenges—whether your focus centers on EGFR pathway blockade, radiation potentiation, immune checkpoint modulation, or novel combination strategies—and we engineer every study protocol to yield reproducible, publication-quality data that withstands the scrutiny of regulatory reviewers and scientific peers alike.

Workflow of FaDu Xenograft Rat Model Construction

Generation of a reproducible FaDu xenograft rat model requires meticulous coordination across cell culture, animal handling, surgical technique, and post-operative care to ensure consistent tumor take rates and valid pharmacological readouts. The workflow described below outlines the standardized protocol employed at Alfa Cytology for establishing reliable FaDu subcutaneous xenografts in immunodeficient rat hosts, with each phase optimized to minimize inter-animal variability and maximize translational relevance for HNSCC drug development.

1. Cell Preparation and Quality Control: FaDu cells are expanded under standardized culture conditions and harvested during mid-logarithmic growth phase using trypsin-EDTA dissociation. Viability is confirmed by trypan blue exclusion assay, with only preparations exceeding 95% viability accepted for inoculation. The cell suspension is washed twice in sterile PBS, counted, and adjusted to the target concentration—typically 5 × 10⁶ cells in 100–200 μL PBS—prior to inoculation.
2. Animal Selection and Acclimation: Immunodeficient nude rats (e.g., Hsd:Rh-rnu) aged 8–10 weeks are procured from accredited commercial breeders and housed for a minimum 7-day acclimation period within our AAALAC-accredited vivarium. Animals are maintained under controlled environmental conditions (12-hour light-dark cycle, 22 ± 2°C, 50–60% relative humidity) with free access to sterilized standard chow and autoclaved water. Body weights are recorded at arrival and at randomization.
3. Tumor Cell Inoculation: Rats are briefly anesthetized using isoflurane inhalation (2–3% in oxygen), and the right flank is shaved and sterilized with alternating povidone-iodine and 70% ethanol scrubs. A single-cell suspension of FaDu cells in 100–200 μL sterile PBS (with or without Matrigel matrix, per protocol specifications) is injected subcutaneously into the prepared site using a 25-gauge needle. Care is taken to deposit the inoculum within the subcutaneous space while avoiding intradermal or intramuscular placement. Animals are returned to their cages and monitored until fully ambulatory.
4. Tumor Monitoring and Measurement: Tumor appearance and growth are monitored by palpation beginning 7 days post-inoculation, with caliper measurements recorded twice weekly once tumors become palpable. Tumor volume is calculated using the modified ellipsoid formula (length × width² × 0.5). Body weights are recorded concurrently to assess treatment-related toxicity. Animals are examined daily for signs of distress, ulceration, or impaired mobility.
5. Treatment Initiation and Dosing: Once tumors reach the protocol-specified starting volume—commonly 100–200 mm³—animals are randomized into treatment and control cohorts using stratification by tumor volume to ensure inter-group balance. Test articles are administered via the designated route (oral gavage, intraperitoneal, intravenous, or subcutaneous) according to the sponsor-defined dosing schedule. Vehicle controls receive equivalent volumes of formulation buffer on an identical schedule.
6. Endpoint Assessment and Necropsy: Studies are terminated upon reaching protocol-defined endpoints, which may include maximal tumor burden (typically 2,000 mm³ or 10% of body weight), significant body weight loss (>20%), tumor ulceration, or deterioration in general condition. At termination, animals are humanely euthanized, and tumors are excised en bloc, weighed, photographed, and allocated for downstream analyses. Blood is collected via cardiac puncture for hematology, clinical chemistry, and pharmacokinetic profiling. Major organs are harvested, weighed, and preserved in 10% neutral buffered formalin for histopathological evaluation.
7. Histopathological and Molecular Analyses: Excised tumors are sectioned and processed for formalin-fixed paraffin embedding (FFPE), with additional portions snap-frozen in liquid nitrogen or stabilized in RNAlater for molecular analyses. Standard histopathological evaluation includes H&E staining for morphology, Ki-67 immunohistochemistry for proliferation index, CD31 staining for microvessel density, and TUNEL assay for apoptotic index. Supplementary analyses such as EGFR expression quantification, p53 status confirmation, and gene expression profiling are available upon request.

Fig 2. FaDu Xenograft Rat Model construction workflow.

Case Study-FaDu Xenograft Rat Model Development

In a recent preclinical program, Alfa Cytology established a subcutaneous FaDu xenograft cohort in nude rats to evaluate the anti-tumor activity of a next-generation EGFR tyrosine kinase inhibitor administered as monotherapy and in combination with fractionated radiation. Following inoculation of 5 × 10⁶ FaDu cells, animals were randomized into vehicle control, single-agent, radiation-only, and combination treatment arms once mean tumor volumes reached approximately 150 mm³. The study incorporated twice-weekly tumor caliper measurements, serial body weight monitoring, and terminal analyses encompassing tumor growth inhibition calculations, Ki-67 proliferation index assessment, and phospho-EGFR Western blot quantification. Pharmacokinetic blood sampling at multiple time points enabled correlation of plasma drug exposure with anti-tumor response, generating an integrated dataset that supported the sponsor's preclinical development milestone. All procedures were conducted under IACUC-approved protocols with full veterinary oversight.

Why Choose Alfa Cytology?

Selecting Alfa Cytology as your partner for FaDu xenograft rat model services means engaging a CRO that combines deep head and neck oncology expertise with operational agility and unwavering commitment to data integrity. Our integrated service model eliminates the friction of multi-vendor coordination, accelerating your path from study conception to actionable results.

• Dedicated head and neck cancer model expertise with extensive experience in FaDu xenograft establishment, ensuring high tumor take rates and reproducible growth kinetics across study cohorts.
• In-house radiation oncology capabilities including small-animal image-guided radiation delivery systems, enabling precise fractionated radiotherapy studies with clinically relevant dosing schedules.
• Flexible study architectures accommodating monotherapy efficacy, combination regimen evaluation, dose-escalation designs, and pharmacokinetic/pharmacodynamic integration tailored to your compound profile.
• Comprehensive biomarker and histopathology services spanning H&E, IHC, IF, digital image analysis, and molecular profiling, all performed within our integrated analytical laboratory.
• AAALAC-accredited vivarium facilities with IACUC-approved protocols, on-site veterinary staff, and stringent animal welfare standards that meet or exceed regulatory expectations.
• Proactive project management with transparent milestone tracking, regular data updates, and rapid responsiveness to protocol amendments or emerging findings.
• Competitive timelines from study initiation to final report, supported by streamlined workflows, established vendor relationships, and dedicated scientific teams.

Contact Us

Whether you are advancing a novel EGFR inhibitor, exploring radiation sensitization strategies, or developing immuno-oncology combinations for head and neck cancer, Alfa Cytology stands ready to support your preclinical program with expertly executed FaDu xenograft rat model services. Contact us today to discuss your study objectives, review our capabilities, or request a customized proposal designed to generate the high-quality data your development pipeline requires.

For research use only. Not intended for any clinical use.